5[5]Robert N, Leyland-Jones B, Asmar L, et al. Phase Ⅲ comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advance breast cancer. Breast Cancer Res Treat, 2002, 76(Supple): 37.
6[6]Henderson C, Berry DA, Denetri GD, et al. Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 2003, 21 (6):976.
8[8]Talbot DC, Moiseyenko V, van Belle S, et al. Randomised, phase Ⅱ trial comparing oral capecitabine (xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer, 2002, 86(9): 1367.
9[9]O′ Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthra cycline-pretreated patients with advanced breast cancer: phase Ⅲ trial results. J Clin Oncol, 2002, 20(12): 2812.
10[10]Venturini M, Durando A, Garrone O, et al. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer, 2003, 97(5):1174.
二级参考文献70
1[1]Gale K E, Andersen J W, Tormey D C, et al. Hormonal treatment for metastatic breast cancer: An Eastern Cooperative Oncology Group phase Ⅲ trial comparing aminoglutethimide to tamoxifen [J]. Cancer, 1994,73:354-361
2[2]Thuerlimann B, Beretta K, Bacchi M, et al. First line fadrozole HCL(CGS 16949A) versus tamoxifen in postmenopausal patients with advanced breast cancer [J]. Ann Onco1,1996,7:471-479
3[3]Gershanovich M, Chaudri H A, Campos D, et al. Letrozole, a new aromatase inhibitor: Randomized trial comparing 0.5 mg and 2.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer [J]. Ann Onco1,1998,9:639-645
4[4]Kaufmann M, Bajetta E, Dirix L Y, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase Ⅲrandomised double-blind trial [J]. J Clin Oncol,2000,18:1399-1411
5[5]Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase Ⅲ study of the International Letrozole Cancer Group [J]. J Clin Oncol,2001,19:2596-2606
6[1]Sondik EJ.Breast cancer trends:incidence,mortality and survival[J]. Cancer, 1994,74: 995.
7[2]Jemal A,Thomas A,Murray T, et al. Cancer statistics,2002[J]. CA Cancer J Clin, 2002,52:23.
8[3]Howe HL,Wingo PA,Thun MJ,et al. Annual reportto the nation on the status of cancer(1973 through 1988),featuring cancers with recent increasing trends[J].J Natl Cancer lnst, 2001,93:824.
9[4]Theobald AJ.Management of advanced breast cancer with endocrine therapy:the role of the primary healthcare team[J].lnt J Clin Pract, 2000,54:665.
10[5]Jaiyesimi IA, Buzdar AU,Decker DA.Use of tamoxifen for breast cancer: twenty-eight years later [J].J Clin Oncol, 1995,13:513.
4Freelove R,Walling AD.Pancreatic cancer:diagnosis and management[J].Am Fam Physician,2006,73 (3):485-492.
5Michaud D S.Epidemiology of pancreatic cancer[J].Minerva Chir,2004,59(2):99-111.
6StornioloAM,EnasNH,Brown CA,et al.An investigation news drug treatment program for patients with gemcitabine:results for over 3000 patients with pancreatic carcinoma[J].Cancer,1999,85(6):1261-1268.
7Burrisha,Moorem J,Anadersen J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].Clin Onco,1997,15(6):2403-2413.
8DiCostanzo F,Carlini P,Doni L,et al.Gemcitabine with or without continuous imfusion 5-Fu in advanced pancreatic cancer:a randomised phaseⅡtrial of the Italian oncology group for clinical research (GOIRC)[J].Br Cancer,2005,93 (2):185-189.
9OettleH,RichardsD,Ramanathan PK,et al.AphaseⅢtrial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer[J].Ann Onco,2005,16(10):1639-1645.
10Rocha Lima CM,GreenMR,Rotche R,et al.Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced ormetastatic pancreatic cancer despite increased tumor response rate[J].Clin Oncol,2004,22(18):3776-3783.
